Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens
Open Access
- 16 November 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 10 (1), 627
- https://doi.org/10.1186/1471-2407-10-627
Abstract
The simplicity and potential of minimal invasive testing using serum from patients make auto-antibody based biomarkers a very promising tool for use in diagnostics of cancer and auto-immune disease. Although several methods exist for elucidating candidate-protein markers, immobilizing these onto membranes and generating so called macroarrays is of limited use for marker validation. Especially when several hundred samples have to be analysed, microarrays could serve as a good alternative since processing macro membranes is cumbersome and reproducibility of results is moderate. Candidate markers identified by SEREX (serological identification of antigens by recombinant expression cloning) screenings of brain and lung tumour were used for macroarray and microarray production. For microarray production recombinant proteins were expressed in E. coli by autoinduction and purified His-tag (histidine-tagged) proteins were then used for the production of protein microarrays. Protein arrays were hybridized with the serum samples from brain and lung tumour patients. Methods for the generation of microarrays were successfully established when using antigens derived from membrane-based selection. Signal patterns obtained by microarrays analysis of brain and lung tumour patients' sera were highly reproducible (R = 0.92-0.96). This provides the technical foundation for diagnostic applications on the basis of auto-antibody patterns. In this limited test set, the assay provided high reproducibility and a broad dynamic range to classify all brain and lung samples correctly. Protein microarray is an efficient means for auto-antibody-based detection when using SEREX-derived clones expressing antigenic proteins. Protein microarrays are preferred to macroarrays due to the easier handling and the high reproducibility of auto-antibody testing. Especially when using only a few microliters of patient samples protein microarrays are ideally suited for validation of auto-antibody signatures for diagnostic purposes.Keywords
This publication has 26 references indexed in Scilit:
- Tumor-associated antigenic pattern in squamous cell carcinomas of the head and neck – Analysed by SEREXEuropean Journal of Cancer, 2013
- Autoantibody Signature in Human Ductal Pancreatic AdenocarcinomaJournal of Proteome Research, 2007
- Cancer Immunomics Using Autoantibody Signatures for Biomarker DiscoveryMolecular & Cellular Proteomics, 2007
- Novel technologies for cancer biomarker discovery: Humoral proteomicsCancer Biomarkers, 2007
- High throughput proteomic strategies for identifying tumour-associated antigensCancer Letters, 2007
- Detection of Protein Biomarkers Using RNA Aptamer Microarrays and Enzymatically Amplified Surface Plasmon Resonance ImagingAnalytical Chemistry, 2007
- Tumor-associated Antigen Arrays for the Serological Diagnosis of CancerMolecular & Cellular Proteomics, 2006
- Antibody Arrays: Technical Considerations and Clinical Applications in CancerClinical Chemistry, 2006
- DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA AptamersTumor Biology, 2006
- Standards for autoantibody testing; Addressing future needs for autoimmune disease and cancer diagnosisCancer Biomarkers, 2005